OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Sara Malik, Shahzeb Hassan, Ahmet Emre Eşkazan
Expert Review of Hematology (2021) Vol. 14, Iss. 11, pp. 975-978
Open Access | Times Cited: 17
Sara Malik, Shahzeb Hassan, Ahmet Emre Eşkazan
Expert Review of Hematology (2021) Vol. 14, Iss. 11, pp. 975-978
Open Access | Times Cited: 17
Showing 17 citing articles:
Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro
L. Pechlivani, Nikoleta Ntemou, Despoina Pantazi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 349-349
Open Access | Times Cited: 6
L. Pechlivani, Nikoleta Ntemou, Despoina Pantazi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 349-349
Open Access | Times Cited: 6
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML
Youlu Pan, Shenxin Zeng, Rongrong Hao, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114442-114442
Closed Access | Times Cited: 20
Youlu Pan, Shenxin Zeng, Rongrong Hao, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114442-114442
Closed Access | Times Cited: 20
Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Emanuela Andretta, Caterina Costa, Consiglia Longobardi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
Emanuela Andretta, Caterina Costa, Consiglia Longobardi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury
Chih-Jen Liu, Lu‐Kai Wang, Fu‐Ming Tsai
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 176-176
Open Access
Chih-Jen Liu, Lu‐Kai Wang, Fu‐Ming Tsai
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 176-176
Open Access
Community detection in Epstein-Barr virus associated carcinomas and role of tyrosine kinase in etiological mechanisms for oncogenesis
S. Chatterjee, B.S. Sanjeev
Microbial Pathogenesis (2023) Vol. 180, pp. 106115-106115
Closed Access | Times Cited: 5
S. Chatterjee, B.S. Sanjeev
Microbial Pathogenesis (2023) Vol. 180, pp. 106115-106115
Closed Access | Times Cited: 5
Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology
Tony J. Zheng, Iván Parra‐Izquierdo, Stéphanie E. Reitsma, et al.
AJP Cell Physiology (2022) Vol. 323, Iss. 4, pp. C1231-C1250
Open Access | Times Cited: 7
Tony J. Zheng, Iván Parra‐Izquierdo, Stéphanie E. Reitsma, et al.
AJP Cell Physiology (2022) Vol. 323, Iss. 4, pp. C1231-C1250
Open Access | Times Cited: 7
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia
Fadi G. Haddad, Ghayas C. Issa, Elias Jabbour, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 7, pp. 751-758
Closed Access | Times Cited: 6
Fadi G. Haddad, Ghayas C. Issa, Elias Jabbour, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 7, pp. 751-758
Closed Access | Times Cited: 6
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting
Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 2, pp. 97-106
Closed Access | Times Cited: 5
Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 2, pp. 97-106
Closed Access | Times Cited: 5
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review
Umut Yılmaz, Batuhan Bulan, Çağrı Belli, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 5, pp. 423-429
Closed Access | Times Cited: 4
Umut Yılmaz, Batuhan Bulan, Çağrı Belli, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 5, pp. 423-429
Closed Access | Times Cited: 4
Developing therapeutic approaches for chronic myeloid leukemia: a review
Veerandra Kumar, Jyotirmayee, Malkhey Verma
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 5, pp. 1013-1029
Closed Access | Times Cited: 4
Veerandra Kumar, Jyotirmayee, Malkhey Verma
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 5, pp. 1013-1029
Closed Access | Times Cited: 4
Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
Surya K. De
Medicinal Chemistry Research (2023) Vol. 32, Iss. 3, pp. 424-433
Closed Access | Times Cited: 2
Surya K. De
Medicinal Chemistry Research (2023) Vol. 32, Iss. 3, pp. 424-433
Closed Access | Times Cited: 2
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies
Lu Sun, Pengcheng Yang, Luan Li, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 193, pp. 106678-106678
Open Access | Times Cited: 1
Lu Sun, Pengcheng Yang, Luan Li, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 193, pp. 106678-106678
Open Access | Times Cited: 1
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2
Yen-Ching Li, Bing-Huan Lin, Megumi Murakami, et al.
European Journal of Pharmacology (2024) Vol. 988, pp. 177231-177231
Closed Access
Yen-Ching Li, Bing-Huan Lin, Megumi Murakami, et al.
European Journal of Pharmacology (2024) Vol. 988, pp. 177231-177231
Closed Access
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care
Giovanni Manfredi Assanto, Emilia Scalzulli, Ida Carmosino, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 11, pp. 963-971
Closed Access | Times Cited: 1
Giovanni Manfredi Assanto, Emilia Scalzulli, Ida Carmosino, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 11, pp. 963-971
Closed Access | Times Cited: 1
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents
Massimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 10, pp. 796-805
Closed Access
Massimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 10, pp. 796-805
Closed Access
慢性骨髄性白血病に対する新たな分子標的療法
Noriyoshi Iriyama
Journal of Nihon University Medical Association (2022) Vol. 81, Iss. 4, pp. 193-196
Open Access
Noriyoshi Iriyama
Journal of Nihon University Medical Association (2022) Vol. 81, Iss. 4, pp. 193-196
Open Access
